Market Update (NYSE:LLY): Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis

[PR Newswire] – INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ — Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety . . . → Read More: Market Update (NYSE:LLY): Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Company Update (NYSE:LLY): Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology